Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

Compare

386 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JANX Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Janux

Therapeutics Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JANX Stock 12 Month Forecast

Average Price Target

$76.57

▲(237.02%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Janux Therapeutics Inc in the last 3 months. The average price target is $76.57 with a high forecast of $100.00 and a low forecast of $36.00. The average price target represents a 237.02% change from the last price of $22.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","101":"$101","43.25":"$43.3","62.5":"$62.5","81.75":"$81.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,43.25,62.5,81.75,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.01,30.77846153846154,36.54692307692308,42.315384615384616,48.08384615384615,53.85230769230769,59.62076923076923,65.38923076923076,71.1576923076923,76.92615384615384,82.69461538461537,88.46307692307691,94.23153846153846,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.01,28.976153846153846,32.94230769230769,36.90846153846154,40.87461538461538,44.840769230769226,48.80692307692307,52.773076923076914,56.73923076923076,60.7053846153846,64.67153846153845,68.63769230769229,72.60384615384615,{"y":76.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.01,25.855384615384615,26.700769230769232,27.546153846153846,28.391538461538463,29.236923076923077,30.082307692307694,30.927692307692308,31.773076923076925,32.61846153846154,33.463846153846156,34.309230769230766,35.15461538461538,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.69,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$76.57

Lowest Price Target$36.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Hold

10.04%

Upside

Reiterated

06/18/25

The overall stock score for Janux Therapeutics Inc is primarily impacted by its strong revenue growth and robust balance sheet, although these are overshadowed by significant profitability challenges and negative cash flow from operations. Bearish market momentum and a negative P/E ratio further weigh down the stock score.

Jeffrey La RosaLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/02/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)

Soumit RoyJonesTrading

JonesTrading

$90

Buy

296.13%

Upside

Reiterated

05/16/25

Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials

Alec StranahanBank of America Securities

Bank of America Securities

$64

Buy

181.69%

Upside

Reiterated

05/14/25

Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$70

Buy

208.10%

Upside

Reiterated

05/09/25

Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position

Jeet MukherjeeBTIG

BTIG

$100

Buy

340.14%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), Immunocore Holdings (NASDAQ: IMCR) and Janux Therapeutics Inc (NASDAQ: JANX)

Oliver McCammonLifeSci Capital

LifeSci Capital

$100

Buy

340.14%

Upside

Reiterated

05/09/25

Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc

George FarmerScotiabank

Scotiabank

$41→$36

Hold

58.45%

Upside

Reiterated

05/09/25

Janux Therapeutics Inc (JANX) Gets a Hold from Scotiabank

Robert DriscollWedbush

Wedbush

$76

Buy

234.51%

Upside

Reiterated

05/09/25

Janux Therapeutics Inc (JANX) Has a New Rating from Wedbush

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$200

Buy

780.28%

Upside

Reiterated

02/28/25

Cantor Fitzgerald reiterates Overweight Rating on Janux Therapeutics (JANX)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $200.00 price target on Janux Therapeutics (NASDAQ: JANX).

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$115→$103

Buy

353.35%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)

Jonathan MillerEvercore ISI

Evercore ISI

$25

Buy

10.04%

Upside

Reiterated

12/03/24

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX) and Kura Oncology (NASDAQ: KURA)

David DaiUBS

UBS

$69

Buy

203.70%

Upside

Initiated

10/24/24

Janux Therapeutics initiated with a Buy at UBSJanux Therapeutics initiated with a Buy at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Hold

10.04%

Upside

Reiterated

06/18/25

Jeffrey La RosaLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/02/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)

Soumit RoyJonesTrading

JonesTrading

$90

Buy

296.13%

Upside

Reiterated

05/16/25

Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials

Alec StranahanBank of America Securities

Bank of America Securities

$64

Buy

181.69%

Upside

Reiterated

05/14/25

Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$70

Buy

208.10%

Upside

Reiterated

05/09/25

Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position

Jeet MukherjeeBTIG

BTIG

$100

Buy

340.14%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), Immunocore Holdings (NASDAQ: IMCR) and Janux Therapeutics Inc (NASDAQ: JANX)

Oliver McCammonLifeSci Capital

LifeSci Capital

$100

Buy

340.14%

Upside

Reiterated

05/09/25

Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc

George FarmerScotiabank

Scotiabank

$41→$36

Hold

58.45%

Upside

Reiterated

05/09/25

Janux Therapeutics Inc (JANX) Gets a Hold from Scotiabank

Robert DriscollWedbush

Wedbush

$76

Buy

234.51%

Upside

Reiterated

05/09/25

Janux Therapeutics Inc (JANX) Has a New Rating from Wedbush

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$200

Buy

780.28%

Upside

Reiterated

02/28/25

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$115→$103

Buy

353.35%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)

Jonathan MillerEvercore ISI

Evercore ISI

$25

Buy

10.04%

Upside

Reiterated

12/03/24

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX) and Kura Oncology (NASDAQ: KURA)

David DaiUBS

UBS

$69

Buy

203.70%

Upside

Initiated

10/24/24

Janux Therapeutics initiated with a Buy at UBSJanux Therapeutics initiated with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Janux Therapeutics Inc

1 Month

xxx

Success Rate

5/10 ratings generated profit

Average Return

+5.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.62% per trade.

3 Months

xxx

Success Rate

5/14 ratings generated profit

Average Return

-14.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -14.69% per trade.

1 Year

Swayampakula RamakanthH.C. Wainwright

Success Rate

5/14 ratings generated profit

Average Return

+79.88%

reiterated a buy rating last month

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +79.88% per trade.

2 Years

xxx

Success Rate

6/14 ratings generated profit

Average Return

+30.98%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +30.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JANX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JANX has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JANX average Analyst price target in the past 3 months is 76.57.

Each month's total comprises the sum of three months' worth of ratings.

JANX Financial Forecast

JANX Earnings Forecast

Next quarter’s earnings estimate for JANX is -$0.46 with a range of -$0.69 to -$0.32. The previous quarter’s EPS was -$0.38. JANX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.

JANX Sales Forecast

Next quarter’s sales forecast for JANX is $273.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. JANX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.

JANX Stock Forecast FAQ

What is JANX’s average 12-month price target, according to analysts?

Based on analyst ratings, Janux Therapeutics Inc’s 12-month average price target is 76.57.

What is JANX’s upside potential, based on the analysts’ average price target?

Janux Therapeutics Inc has 237.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JANX a Buy, Sell or Hold?

Janux Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Janux Therapeutics Inc’s price target?

The average price target for Janux Therapeutics Inc is 76.57. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $36.00. The average price target represents 237.02% Increase from the current price of $22.72.

What do analysts say about Janux Therapeutics Inc?

Janux Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of JANX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

JANX Analyst Ratings

JANX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Janux Therapeutics Inc

JANX Analyst Recommendation Trends

JANX Financial Forecast

JANX Earnings Forecast

JANX Sales Forecast

JANX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts